Organizers claimed that nearly 2 million Hong Kong protesters took to the streets Sunday in a rally to demand the city's top official resign a day after she suspended — but...China Politicsread more
African swine fever, which has already ravaged pig herds in China and pushed up food prices there, could also drive up inflation in the other emerging markets, according to...Asia Economyread more
Consumer goods giant Unilever has taken the unusual step of having some of its marketing staff read their own DNA profiles to see whether finding out about their heritage has...Marketing.Media.Moneyread more
Stocks in Asia traded mixed on Monday as investors await a U.S. Federal Reserve meeting set to happen later in the week stateside.Asia Marketsread more
In the survey, 66% of Democratic primary voters say they'd be enthusiastic or comfortable about Biden as their nominee to take on President Trump in the 2020 election. Just...Politicsread more
Heavy rains caused unprecedented delays in planting this year and contributed to record floods across the central United States.Agricultureread more
Target's registers were down on Saturday for several hours preventing customers from checking out.Retailread more
Although Cook did not mention companies by name, his commencement speech in Silicon Valley's backyard mentioned data breaches, privacy violations, and even made reference to...Technologyread more
U.S. ambassador to Israel David Friedman called the gesture a "birthday present" to Trump, who turned 73 on Friday.Politicsread more
The outlook for Germany's economy and political stability are more uncertain than ever, writes Michael Ivanovitch.World Economyread more
The agreement, which is on the framework for the plan of adjustment, provide for more than a 60% average haircut for all $35 billion, a 36% haircut on pre-2012 general...Bondsread more
A glut of patients who were prescribed Repatha, Amgen's treatment for high cholesterol, but couldn't pay for the pricey treatment, were top of mind in the company's decision to cut the drug's cost by 60 percent, Amgen Chairman and CEO Bob Bradway said Monday.
In October, Amgen cut the price for a biweekly dose of Repatha, bringing the annual $14,100 total, before discounts and rebates, to roughly $5,850. On Monday, the biotechnology giant announced another 60 percent price slash, this time to the cost of the monthly dose.
"We found too many patients were prescribed this therapy, but were struggling to pay for it at the pharmacy counter," Bradway told CNBC in an interview with Jim Cramer. "The reaction so far from physicians and from patients has been very, very encouraging."
While the positive reaction in itself may not make up for the money Amgen will lose, the number of patients that will reconsider taking the drug at its lower price was encouraging enough for Bradway, who has been CEO of Amgen since 2012.
"What we're finding is that patients that were walking away from the prescription — so, patients whose doctors had already identified them as being at high risk for heart attack and stroke — are now being able to get access to the medicine," Bradway said on "Mad Money."
Repatha treats high LDL cholesterol, the kind that heightens the risk of heart attack and stroke. It's also the main reason why $600 billion a year is spend on cardiovascular disease, Bradway said, adding that Repatha lowers LDL levels in patients by 63 percent, on average.
Amgen's stock rose 1.35 percent Monday, settling at $198.07 a share. The company made headlines in 2018 for pioneering Aimovig, the first drug specifically intended for migraine sufferers, and has seen that franchise grow by double digits.
Disclosure: Cramer's charitable trust owns shares of J.P. Morgan and Amgen.